JO3784B1 - الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان - Google Patents
الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطانInfo
- Publication number
- JO3784B1 JO3784B1 JOP/2016/0162A JOP20160162A JO3784B1 JO 3784 B1 JO3784 B1 JO 3784B1 JO P20160162 A JOP20160162 A JO P20160162A JO 3784 B1 JO3784 B1 JO 3784B1
- Authority
- JO
- Jordan
- Prior art keywords
- treatment
- cancer
- combination
- combined use
- csf antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
يتعلق الاختراع الحالي بتركيبة صيدلانية تشتمل على مضاد PD-1 ومضاد M-CSF. يمكن تعاطي التوليفة الحالية بشكل مستقل أو بشكل منفصل، بكمية تكون فعالة علاجياً لعلاج السرطان. يوفر الاختراع أيضاً استخدام هذه التوليفة لتصنيع دواء؛ استخدام هذه التوليفة كدواء؛ مجموعة من جزء يشتمل على هذه التوليفة؛ وطريقة لعلاج هذه التوليفة.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562198384P | 2015-07-29 | 2015-07-29 | |
US201662352637P | 2016-06-21 | 2016-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3784B1 true JO3784B1 (ar) | 2021-01-31 |
Family
ID=56682136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2016/0162A JO3784B1 (ar) | 2015-07-29 | 2016-07-28 | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان |
Country Status (19)
Country | Link |
---|---|
US (1) | US11001628B2 (ar) |
EP (1) | EP3328425B1 (ar) |
JP (1) | JP6840127B2 (ar) |
KR (1) | KR20180034426A (ar) |
CN (1) | CN108136003A (ar) |
AU (1) | AU2016300208B2 (ar) |
BR (1) | BR112018000212A2 (ar) |
CA (1) | CA2991857A1 (ar) |
CL (1) | CL2018000222A1 (ar) |
HK (1) | HK1247848A1 (ar) |
IL (1) | IL256691A (ar) |
JO (1) | JO3784B1 (ar) |
MX (1) | MX2018001263A (ar) |
PH (1) | PH12018500174A1 (ar) |
RU (1) | RU2742494C2 (ar) |
SA (1) | SA518390834B1 (ar) |
TN (1) | TN2017000554A1 (ar) |
TW (1) | TWI735456B (ar) |
WO (1) | WO2017017623A1 (ar) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
KR102317574B1 (ko) | 2015-11-18 | 2021-10-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
AR112603A1 (es) * | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
CN112654365A (zh) * | 2018-07-12 | 2021-04-13 | 科尔沃斯制药股份有限公司 | 用于检测和治疗具有腺苷途径激活的癌症的方法 |
WO2020044252A1 (en) * | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
EP3976090A1 (en) | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Combination therapies using cdk inhibitors |
JP2022536511A (ja) * | 2019-06-13 | 2022-08-17 | シートムエックス セラピューティクス,インコーポレイテッド | 癌の処置のための併用療法での活性化可能抗pdl1抗体および抗ctla-4抗体の使用 |
JP2022537151A (ja) * | 2019-06-13 | 2022-08-24 | シートムエックス セラピューティクス,インコーポレイテッド | 癌の処置のためのネオアジュバント併用療法での活性化可能抗pdl1抗体および抗ctla-4抗体の使用 |
WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业(上海)股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
PT2311873T (pt) * | 2004-01-07 | 2018-11-20 | Novartis Vaccines & Diagnostics Inc | Anticorpo monoclonal específico para m-csf e respetivos usos |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CA2661319C (en) * | 2006-08-23 | 2015-12-01 | Yeda Research And Development Co. Ltd | Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses |
AU2007296259A1 (en) * | 2006-09-15 | 2008-03-20 | Janssen Pharmaceutica Nv | Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors |
US8747847B2 (en) | 2008-02-11 | 2014-06-10 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
KR20110074850A (ko) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 길항제 및 그의 사용 방법 |
WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
CA2920113A1 (en) * | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
-
2016
- 2016-07-27 TN TNP/2017/000554A patent/TN2017000554A1/en unknown
- 2016-07-27 EP EP16750495.0A patent/EP3328425B1/en active Active
- 2016-07-27 JP JP2018504105A patent/JP6840127B2/ja active Active
- 2016-07-27 CN CN201680044470.5A patent/CN108136003A/zh active Pending
- 2016-07-27 CA CA2991857A patent/CA2991857A1/en not_active Abandoned
- 2016-07-27 US US15/879,064 patent/US11001628B2/en active Active
- 2016-07-27 MX MX2018001263A patent/MX2018001263A/es unknown
- 2016-07-27 RU RU2018106876A patent/RU2742494C2/ru active
- 2016-07-27 AU AU2016300208A patent/AU2016300208B2/en not_active Ceased
- 2016-07-27 BR BR112018000212A patent/BR112018000212A2/pt not_active IP Right Cessation
- 2016-07-27 WO PCT/IB2016/054487 patent/WO2017017623A1/en active Application Filing
- 2016-07-27 KR KR1020187002247A patent/KR20180034426A/ko not_active Application Discontinuation
- 2016-07-28 JO JOP/2016/0162A patent/JO3784B1/ar active
- 2016-07-29 TW TW105124178A patent/TWI735456B/zh not_active IP Right Cessation
-
2018
- 2018-01-01 IL IL256691A patent/IL256691A/en unknown
- 2018-01-23 PH PH12018500174A patent/PH12018500174A1/en unknown
- 2018-01-26 CL CL2018000222A patent/CL2018000222A1/es unknown
- 2018-01-29 SA SA518390834A patent/SA518390834B1/ar unknown
- 2018-06-07 HK HK18107446.5A patent/HK1247848A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PH12018500174A1 (en) | 2018-07-30 |
RU2742494C2 (ru) | 2021-02-08 |
AU2016300208A1 (en) | 2018-02-01 |
TW201718011A (zh) | 2017-06-01 |
CN108136003A (zh) | 2018-06-08 |
CA2991857A1 (en) | 2017-02-02 |
RU2018106876A (ru) | 2019-08-28 |
US20180222973A1 (en) | 2018-08-09 |
SA518390834B1 (ar) | 2021-03-02 |
JP6840127B2 (ja) | 2021-03-10 |
BR112018000212A2 (pt) | 2018-09-04 |
JP2018525367A (ja) | 2018-09-06 |
AU2016300208B2 (en) | 2019-08-08 |
RU2018106876A3 (ar) | 2020-07-17 |
HK1247848A1 (zh) | 2018-10-05 |
MX2018001263A (es) | 2018-04-13 |
CL2018000222A1 (es) | 2018-07-13 |
EP3328425A1 (en) | 2018-06-06 |
KR20180034426A (ko) | 2018-04-04 |
IL256691A (en) | 2018-03-29 |
TWI735456B (zh) | 2021-08-11 |
EP3328425B1 (en) | 2021-08-25 |
US11001628B2 (en) | 2021-05-11 |
TN2017000554A1 (en) | 2019-04-12 |
WO2017017623A1 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
PH12018500642A1 (en) | Anti-garp antibody | |
PH12016501790A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
PH12016502355B1 (en) | Pharmaceutical composition | |
MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
PH12016502352A1 (en) | Pharmaceutical composition | |
TW201613578A (en) | Pharmaceutical combinations | |
MX2016004114A (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
MX2016006894A (es) | Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. | |
MX362905B (es) | Tratamiento de combinacion. | |
MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
MX2019007360A (es) | Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina. | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
TW201613926A (en) | Inhibitors of bruton's tyrosine kinase |